Screener
Alto Neuroscience ANRO Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001999480-26-000012
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Prepaid expenses and other assets | (4,130) | (1,692) |
| Accounts payable | 1,490 | (266) |
| Accrued liabilities and other liabilities | (1,753) | (2,701) |
| Net cash used in operating activities | (27,091) | (16,556) |
| Cash Flows from Investing Activities: | ||
| Capital expenditures | (556) | (24) |
| Net cash used in investing activities | (556) | (24) |
| Cash Flows from Financing Activities: |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Alto Neuroscience's operating cash flow?
- Alto Neuroscience (ANRO) reported operating cash flow of -$27.09M in Q1 2026.
- How has Alto Neuroscience's operating cash flow changed year-over-year?
- Alto Neuroscience's operating cash flow decreased by 63.6% year-over-year, from -$16.56M to -$27.09M.
- What is the long-term trend for Alto Neuroscience's operating cash flow?
- Over 2 years (2023 to 2025), Alto Neuroscience's operating cash flow has grown at a 24.4% compound annual growth rate (CAGR), from -$33.45M to -$51.77M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Alto Neuroscience's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude